Adults 19 to 65 with medical conditions that increase their risk of pneumococcal disease may receive PCV20. Children or teens at higher risk may receive PCV15. PCV13, also known as Prevnar 13 ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar 13 capturing almost $6 billion of that last year from its use ...

Prevnar, suitable for all individuals six weeks and older, offers protection against seven new serotypes, or variants of bacteria that cause pneumococcal disease, in addition to the 13 already ...

a Pfizer vaccine that protects against 20 pneumococcal strains—seven more than the company’s blockbuster Prevnar 13. But others are on the big pharma company’s heels with vaccine candidates ...

The CDC revised its pneumococcal pneumonia shot recommendation, saying there is a substantial increase in the risk for ...

It had a safety profile similar to Pfizer's market-leading Prevnar 20 ... It expects the pneumococcal vaccine market to reach a value of around $13 billion by 2027, driven primarily by growth ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

The trial was designed to compare immune responses in patients 60 years of age and older after Prevnar 20 administration to responses in a control group receiving 13-valent pneumococcal conjugate ...

Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key to the success of Prevnar in North America.

Drug major Merck & Co. (MRK) announced Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use or ...